Understanding the structure of the beta-Klotho molecule could lead to new ways of tackling diseases such as diabetes, obesity and some cancers, the researchers said in a study published in the latest issue of the journal Nature, quoted Wednesday by the Press Association. .
Klotho protein, which can take two forms, is found on the surface of cells in certain tissues, and studies have shown that it is involved in processes that slow down the aging process.
The molecule adheres to a family of hormones, known as fibroblast growth factors (FGF), which regulate critical metabolic processes in the liver, kidneys, brain and other organs.
Drugs that act on the Klotho-FGF pathway, either by stimulating it or blocking it, have the potential to fight a whole range of conditions, according to the American research team.
The new study that reveals the 3D shape of the molecule has shown that beta-Klotho is the most important activator of FGF21, a key hormone generated during food deprivation.
When it adheres to beta-Klotho, the hormone triggers insulin sensitivity and glucose metabolism, leading to weight loss.
This pathway has implications for the treatment of type 2 diabetes and obesity.
“In animals and in clinical trials with FGF21, it has been shown that it can stimulate calorie burning without altering dietary intake, and we now understand how the biological activity of FGF21 can be improved,” said lead researcher Dr. Joseph Schlessinger of Yale School of Medicine.
Schlessinger said the next step in the research will be to “produce more effective hormones, create new powerful blockers, conduct animal studies and continue research.”
In Greek mythology, Klotho (or Clotho) was one of the three goddesses of destiny, Moirae (Cursed), who ruled the destiny of people, one of whom twisted, another unraveled and the last cut the thread of life when the moment of death came.
Read also:
– .
